NCT04542447View on ClinicalTrials.gov

To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.

PHASE1UnknownINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions

Covid19

Interventions

DRUG

Nuvastatic

Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy

Trial Locations (1)

Unknown

RECRUITING

Navin Hospital, Ghaziabad

Sponsors

Lead Sponsor

Natureceuticals Sdn Bhd

All Listed Sponsors

lead

Natureceuticals Sdn Bhd

INDUSTRY

NCT04542447 - To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients. | Biotech Hunter | Biotech Hunter